Close Menu

JP Morgan Healthcare Conference

Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.

Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.

Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.